TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Highmark to increase premiums, limit access to health care in new plans
  2. Coca-Cola shaves incentives for executives
  3. Retirement planning is about more than just money
  4. Oil, gas industry boom leads to expansion of laws in Pennsylvania
  5. Consol Energy cutting retiree health benefits, phasing out pension
  6. Roundup: Pittsburgh Corning plan confirmed; II-VI reorganizes segments; more
  7. Canadian company wins bid for casino
  8. Bond experts fear inevitable sell-off
  9. Hospitals, doctors in Pa. received $32M in 5 months from drug, medical device companies
  10. New models, China sales key to GM’s future, Barra tells investors
  11. Truck deals give auto sales a lift
Subscribe today! Click here for our subscription offers.